Xortx Therapeutics prices 1.75M shares at 63c in registered direct offering

XORTX Therapeutics (XRTX) entered into a securities purchase agreement with an institutional investor for the purchase and sale of 1,746,631 common shares in a registered direct offering at a purchase price of 63c per common share. The closing of the Offering is expected to occur on or about October 22, subject to the satisfaction of customary closing conditions and approval from the TSX Venture Exchange. The gross proceeds from the Offering are expected to be $1.1M, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes. D. Boral Capital is acting as sole placement agent for the Offering.